MEMPHIS, TN - May 18, 2009 - ACORN CRO, an oncology -focused CRO, has developed proprietary technology known as STAR (Site Tracking And Recruitment). The introduction of this dedicated technology tool will speed the site selection process as it automates the study feasibility process. "STAR was developed under the guidance of ACORN CRO's experienced project managers who sought to save valuable time during the study start-up phase. The resulting system delivers solutions that provide meaningful cost benefits to both sponsors and participating sites," remarked Edward J. Stepanski, PhD, COO.
STAR increases transparency and efficiency in the study feasibility/site selection process. The Site Repository contains all known information about each oncology research site, and enables rapid selection of potential study sites based upon sponsor/study requirements. It also reduces the need for sites to complete repetitive tasks and is estimated to save approximately 75% of the time sites traditionally spend on com pleting study feasibility forms. Through STAR, sponsors are able to v iew a report summarizing site identification metrics in real time. Sponsors will appreciate that STAR automatically sends reminder notifications throughout the process, allows complete tracking of the status of each site contacted, and reduces the time needed to definitively identify study sites.
"STAR is yet another way in which ACORN CRO leverages technology to provide added value and efficiency for its customers. STAR substantially speeds up the study start-up process which results in impressive economies of scale," added Kristie Lively, Vice President.
ACORN CRO will showcase STAR at the annual DIA meeting in San Diego, June 22-24, 2009 in booth #2039.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.